Structure via PubChem · Public domain (PubChem)
apraclonidine
Sign in to saveAlso known as AL-02145, Iopidine®, 4-Aminoclonidine, Apraclonidinum, Apraclonidina
Apraclonidine (INN), also known under the brand name Iopidine, is a sympathomimetic used in glaucoma therapy. It is an α2 adrenergic receptor agonist and a weak α1 adrenergic receptor agonist.
Key facts
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 457136476
- Drug.IUPAC_name
- 2,6-Dichloro-N- (4,5-dihydro-1H-imidazol-2-yl) benzene-1,4-diamine
- Drug.image
- Apraclonidine structure.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 185
- Drug.tradename
- Iopidine
- Drug.MedlinePlus
- a608005
- Drug.legal_UK
- POM
- Drug.legal_US
- Rx-only
- Drug.legal_status
- Rx-only
- Drug.routes_of_administration
- Topical (ophthalmic solution)
- Drug.protein_bound
- 98.7%
- Drug.elimination_half life
- 8 hours
- Drug.IUPHAR_ligand
- 7117
- Drug.CAS_number
- 66711-21-5
- Drug.ATC_prefix
- S01
- Drug.ATC_suffix
- EA03
via Wikipedia infobox
Chemical data
- Formula
- C9H10Cl2N4
- Molecular weight
- 245.11 g/mol
- IUPAC name
- 2,6-dichloro-1-N-(4,5-dihydro-1H-imidazol-2-yl)benzene-1,4-diamine
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 1987
- Admin. routes
- topical
- Indications
- Myasthenia gravis, glaucoma
via ChEMBL · EBI
Research
498 papers- Apraclonidine.2006
- Apraclonidine-An eye opener.Frontiers in ophthalmology · 2022
- Apraclonidine in the treatment of ptosis.Journal of the neurological sciences · 2017
- Apraclonidine and my pupil.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2011
- Botulinum toxin-induced blepharoptosis: Anatomy, etiology, prevention, and therapeutic options.Journal of cosmetic dermatology · 2021
via PubMed
~2 min read
Encyclopedic overview
4 sectionsContents
- Medical uses
- References
- Further reading
- External links
Apraclonidine (INN), also known under the brand name Iopidine, is a sympathomimetic used in glaucoma therapy. It is an α2 adrenergic receptor agonist and a weak α1 adrenergic receptor agonist.
Topical apraclonidine is administered at a concentration of 1% for the prevention and treatment of post-surgical intraocular pressure (IOP) elevation and 0.5% for short-term adjunctive therapy in patients on maximally tolerated medical therapy who require additional reduction of IOP. One drop is usually added one hour prior to laser eye surgery and another drop is given after the procedure is complete.
Excerpted from Wikipedia’s “apraclonidine” article, available under the CC BY-SA 4.0 licence.